Bristol-Myers Squibb Co (NYSE:BMY) – William Blair issued their Q1 2019 earnings estimates for Bristol-Myers Squibb in a research note issued on Tuesday. William Blair analyst M. Phipps anticipates that the biopharmaceutical company will post earnings per share of $0.95 for the quarter. William Blair also issued estimates for Bristol-Myers Squibb’s Q2 2019 earnings at $0.97 EPS, Q3 2019 earnings at $0.98 EPS, Q4 2019 earnings at $1.00 EPS, FY2019 earnings at $3.91 EPS and FY2020 earnings at $4.42 EPS.
A number of other analysts have also commented on BMY. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Vetr downgraded shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $59.70 price objective for the company. in a research report on Thursday, December 28th. SunTrust Banks raised shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Barclays raised their price objective on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. Finally, BMO Capital Markets set a $49.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $65.58.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 33.68%. The firm had revenue of $5.45 billion during the quarter, compared to the consensus estimate of $5.35 billion. During the same period in the prior year, the firm earned $0.63 EPS. The business’s revenue was up 3.9% on a year-over-year basis.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were issued a $0.40 dividend. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 annualized dividend and a yield of 2.60%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 271.19%.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of Bristol-Myers Squibb stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total transaction of $335,172.00. Following the completion of the transaction, the executive vice president now owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Theodore R. Samuels II bought 4,000 shares of Bristol-Myers Squibb stock in a transaction on Friday, December 15th. The shares were bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now directly owns 22,000 shares in the company, valued at $1,370,600. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.
A number of hedge funds have recently bought and sold shares of BMY. Tradewinds Capital Management LLC grew its holdings in shares of Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 500 shares during the last quarter. Delphi Private Advisors LLC purchased a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at $108,000. Atlantic Trust LLC purchased a new stake in shares of Bristol-Myers Squibb during the 2nd quarter valued at $111,000. Massey Quick Simon & CO. LLC grew its stake in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after buying an additional 1,492 shares during the period. Finally, Blue Chip Partners Inc. grew its stake in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 15 shares during the period. 69.70% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “Bristol-Myers Squibb Co Forecasted to Post Q1 2019 Earnings of $0.95 Per Share (BMY)” was originally published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/07/bristol-myers-squibb-co-forecasted-to-post-q1-2019-earnings-of-0-95-per-share-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.